GH Strangle Strategy
GH (Guardant Health, Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients.
GH (Guardant Health, Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $19.79B, a beta of 1.62 versus the broader market, a 52-week range of 40.35-151.85, average daily share volume of 2.5M, a public-listing history dating back to 2018, approximately 2K full-time employees. These structural characteristics shape how GH stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.62 indicates GH has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on GH?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current GH snapshot
As of June 29, 2026, spot at $153.69, ATM IV 53.00%, IV rank 5.14%, expected move 15.19%. The strangle on GH below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on GH specifically: GH IV at 53.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a GH strangle, with a market-implied 1-standard-deviation move of approximately 15.19% (roughly $23.35 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GH expiries trade a higher absolute premium for lower per-day decay. Position sizing on GH should anchor to the underlying notional of $153.69 per share and to the trader's directional view on GH stock.
GH strangle setup
The GH strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GH near $153.69, the first option leg uses a $160.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GH chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GH shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $160.00 | $4.05 |
| Buy 1 | Put | $145.00 | $4.10 |
GH strangle risk and reward
- Net Premium / Debit
- -$815.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$815.00
- Breakeven(s)
- $136.85, $168.15
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
GH strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on GH. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$13,684.00 |
| $33.99 | -77.9% | +$10,285.94 |
| $67.97 | -55.8% | +$6,887.88 |
| $101.95 | -33.7% | +$3,489.82 |
| $135.93 | -11.6% | +$91.76 |
| $169.91 | +10.6% | +$176.30 |
| $203.89 | +32.7% | +$3,574.36 |
| $237.87 | +54.8% | +$6,972.42 |
| $271.85 | +76.9% | +$10,370.48 |
| $305.84 | +99.0% | +$13,768.54 |
When traders use strangle on GH
Strangles on GH are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GH chain.
GH thesis for this strangle
The market-implied 1-standard-deviation range for GH extends from approximately $130.34 on the downside to $177.04 on the upside. A GH long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current GH IV rank near 5.14% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on GH at 53.00%. As a Healthcare name, GH options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GH-specific events.
GH strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GH positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GH alongside the broader basket even when GH-specific fundamentals are unchanged. Always rebuild the position from current GH chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on GH?
- A strangle on GH is the strangle strategy applied to GH (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With GH stock trading near $153.69, the strikes shown on this page are snapped to the nearest listed GH chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are GH strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the GH strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 53.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$815.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GH strangle?
- The breakeven for the GH strangle priced on this page is roughly $136.85 and $168.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GH market-implied 1-standard-deviation expected move is approximately 15.19%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on GH?
- Strangles on GH are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GH chain.
- How does current GH implied volatility affect this strangle?
- GH ATM IV is at 53.00% with IV rank near 5.14%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.